Nasus Pharma LTD. reports a Return on Equity (ROE) of -211.56%.

What is NSRX's dividend yield?

Nasus Pharma LTD. offers a dividend yield of 0.00%.

What is NSRX's Quality Score?

Our AI rates NSRX's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy NSRX?

Our AI Timing Score for NSRX is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does NSRX belong to?

Nasus Pharma LTD. is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE MKT exchange

Nasus Pharma LTD. (NSRX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2025-12-31)

NSRX AI Analysis Summary

Our AI summary for NSRX: Nasus Pharma LTD. (NYSE MKT), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at ROE of -211.56%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

NSRX

Nasus Pharma LTD.

US:NYSE MKT STOCK Healthcare >> Drug Manufacturers - General News 95

USD 3.03

-0.15 (-4.72%) Day Change

Watchlist Portfolio Compare Chart

0.81

D/E

-211.6%

ROE

-117.0%

ROA

0.00%

Div Yield

Data partially updated

NASUS PHARMA LTD.
TYPE: STOCK
MARKET: NYSE MKT

Compare Watchlist Myport

USD 3.03 Price -0.15 (-4.72%) Day Change	NEWS SCORE: 95

NSRX, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

36%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	95
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	3.03
PBV / Sector	9.87 / 2.68
Earning Per Share	-0.65

PE / Sector	N/A / 27.65
PEG or PE/Growth / Sector	N/A / 0.28
Average 1M Daily Value	0.04 M GREAT
Average 1W Daily Value	0.03 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 17.30
NPM Average (%) / Sector	N/A / 17.60
NPM Change Average (%) / Sector	N/A / 92.67
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-117.03 / 8.73
ROA Average (%) / Sector	-244.43 / 8.56
ROA Change Average (%) / Sector	-32.42 / 94.23
ROE (%) / Sector	-211.56 / 26.78
ROE Average (%) / Sector	-18.69 / 13.05
ROE Change Average (%) / Sector	-175.40 / 96.64
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 2.40
Dividend Average (%) / Sector	N/A / 3.39
Dividend Change Average (%) / Sector	N/A / 4.92

Registration Details

Analyze Date	2026-08-01 08:00:14
Symbol	NSRX
Name	NASUS PHARMA LTD.
Sector	Healthcare >> Drug Manufacturers - General
Market	NYSE MKT
Listed Shares	11.71 M
Par Value	N/A
Calculated From	YearEnd
Sign	N/A
Market Cap (M.USD) / Sector Average	27.32 / 256,404.20

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Yigal Alon 65, Tel Aviv-Yafo, Israel, 6744317

Phone: 972 3 573 6632

Website: https://www.nasuspharma.com

Sector: Healthcare >> Drug Manufacturers - General

Description: Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.